Biolase Inc. said it regained compliance with the Nasdaq Capital Market's $1 minimum bid price listing requirement.
The Irvine, Calif.-based medical device company recently implemented a 1-for-5 reverse stock split to regain compliance.
Biolase received the noncompliance notice in August 2017. The company failed to raise its bid price in time, but it was granted a 180-day extension to regain compliance.
